A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia
Trial status: Authorised
Percent change from baseline of morning A4 at Week 2 Percent change from baseline of morning 17-OHP at Week 32 Proportion of participants with morning pre-GC A4 ≤ULN who are on physiologic GC replacement at Week 32 Percent change from baseline in GC daily dose when morning post-GC A4 ≤ULN at week 32
Proportion of participants with morning post-GC A4 ≤ULN who are on physiologic GC replacement at Week 32
Description
Percent change from baseline of morning A4 at Week 2 Percent change from baseline of morning 17-OHP at Week 32 Proportion of participants with morning pre-GC A4 ≤ULN who are on physiologic GC replacement at Week 32 Percent change from baseline in GC daily dose when morning post-GC A4 ≤ULN at week 32
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 54 participants
БГ